Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.
Celularity Inc. (Nasdaq: CELU) has expanded its commercial portfolio of placental-derived advanced biomaterial products by acquiring Rebound™, a full thickness placental-derived allograft matrix product, from Sequence LifeScience, Inc. This acquisition is expected to contribute significantly to Celularity's fourth quarter 2024 sales and help fulfill the company's projected full-year 2024 biomaterial sales.
Celularity's Chairman, CEO, and founder, Robert J. Hariri, M.D., Ph.D., highlighted that the company's biomaterial product sales in the first half of 2024 exceeded $24 million, surpassing their full-year sales in 2023. The addition of Rebound complements Celularity's existing portfolio and enhances its ability to address a broader patient population in wound care and soft tissue repair.
This strategic acquisition aligns with Celularity's vision of expanding its offerings and reinforces its leadership in the field of placental-derived biomaterials. The company continues to differentiate itself in the regenerative medicine market by leveraging the unique properties of placental tissues to provide advanced, natural solutions designed to improve healing outcomes.
Celularity Inc. (Nasdaq: CELU) ha ampliato il suo portafoglio commerciale di prodotti avanzati a base di biomateriali derivati dalla placenta acquisendo Rebound™, un prodotto a matrice di allograft derivato dalla placenta a tutto spessore, da Sequence LifeScience, Inc. Si prevede che questa acquisizione contribuirà in modo significativo alle vendite di Celularity nel quarto trimestre del 2024 e aiuterà a soddisfare le proiezioni di vendite annuali per il 2024 dei biomateriali.
Il Presidente, CEO e fondatore di Celularity, Robert J. Hariri, M.D., Ph.D., ha sottolineato che le vendite di prodotti biomateriali dell'azienda nella prima metà del 2024 hanno superato i 24 milioni di dollari, superando il totale delle vendite annuali del 2023. L'aggiunta di Rebound completa il portafoglio esistente di Celularity e migliora la sua capacità di affrontare una popolazione di pazienti più ampia nel trattamento delle ferite e nella riparazione dei tessuti molli.
Questa acquisizione strategica si allinea con la visione di Celularity di espandere le proprie offerte e rinforza la sua leadership nel campo dei biomateriali derivati dalla placenta. L'azienda continua a differenziarsi nel mercato della medicina rigenerativa sfruttando le proprietà uniche dei tessuti placentari per fornire soluzioni avanzate e naturali progettate per migliorare i risultati di guarigione.
Celularity Inc. (Nasdaq: CELU) ha ampliado su portafolio comercial de productos avanzados de biomateriales derivados de la placenta mediante la adquisición de Rebound™, un producto de matriz aloinjerto de espesor completo originado de placenta, de Sequence LifeScience, Inc. Se espera que esta adquisición contribuya significativamente a las ventas de Celularity en el cuarto trimestre de 2024 y ayude a cumplir las proyecciones de ventas de biomateriales para todo el año 2024.
El presidente, CEO y fundador de Celularity, Robert J. Hariri, M.D., Ph.D., destacó que las ventas de productos de biomateriales de la empresa en la primera mitad de 2024 superaron los 24 millones de dólares, superando las ventas anuales totales de 2023. La adición de Rebound complementa el portafolio existente de Celularity y mejora su capacidad para atender a una población de pacientes más amplia en cuidado de heridas y reparación de tejidos blandos.
Esta adquisición estratégica se alinea con la visión de Celularity de expandir su oferta y refuerza su liderazgo en el campo de los biomateriales derivados de la placenta. La empresa sigue diferenciándose en el mercado de la medicina regenerativa al aprovechar las propiedades únicas de los tejidos placentarios para proporcionar soluciones avanzadas y naturales diseñadas para mejorar los resultados de cicatrización.
셀룰라리티 주식회사 (Nasdaq: CELU)는 Sequence LifeScience, Inc.로부터 전층 태반 유래 동종이식 행렬 제품인 Rebound™를 인수하여 태반 유래 첨단 바이오 소재 제품의 상업적 포트폴리오를 확장하였습니다. 이번 인수는 2024년 4분기 셀룰라리티의 매출에 중요한 기여를 할 것으로 예상되며, 회사의 2024년 연간 바이오 소재 매출 목표를 달성하는 데 도움을 줄 것입니다.
셀룰라리티의 회장 겸 CEO이자 창립자 로버트 J. 하리리 (Robert J. Hariri, M.D., Ph.D.)는 2024년 상반기 회사의 바이오 소재 제품 판매가 2,400만 달러를 초과하여 2023년 연간 매출을 상회했다고 강조했습니다. Rebound의 추가는 셀룰라리티의 기존 포트폴리오를 보완하고 상처 치료 및 연조직 복구 분야에서 더 넓은 환자 집단을 다룰 수 있는 능력을 향상시킵니다.
이번 전략적 인수는 셀룰라리티의 제품 확장 비전과 일치하며 태반 유래 바이오 소재 분야에서의 리더십을 강화합니다. 회사는 태반 조직의 독특한 특성을 활용하여 치유 결과를 개선하기 위해 고급 자연 솔루션을 제공하며, 재생 의학 시장에서 스스로를 차별화하고 있습니다.
Celularity Inc. (Nasdaq: CELU) a élargi son portefeuille commercial de produits biomatériaux avancés dérivés du placenta en acquérant Rebound™, un produit de matrice allogreffe de pleine épaisseur dérivé du placenta, auprès de Sequence LifeScience, Inc. Cette acquisition devrait contribuer de manière significative aux ventes de Celularity au quatrième trimestre 2024 et aider à réaliser les prévisions de ventes annuelles de biomatériaux pour 2024.
Robert J. Hariri, M.D., Ph.D., Président et CEO de Celularity, a souligné que les ventes de produits biomatériaux de l'entreprise au premier semestre 2024 ont dépassé 24 millions de dollars, surpassant ainsi les ventes totales de 2023. L'ajout de Rebound complète le portefeuille existant de Celularity et améliore sa capacité à répondre à une population de patients plus large dans le domaine des soins des plaies et de la réparation des tissus mous.
Cette acquisition stratégique s'aligne avec la vision de Celularity d'élargir son offre et renforce son leadership dans le domaine des biomatériaux dérivés du placenta. L'entreprise continue de se distinguer sur le marché de la médecine régénérative en tirant parti des propriétés uniques des tissus placentaires pour fournir des solutions avancées et naturelles conçues pour améliorer les résultats de guérison.
Celularity Inc. (Nasdaq: CELU) hat sein kommerzielles Portfolio an fortschrittlichen biopolymerbasierenden Produkten, die aus der Plazenta abgeleitet sind, durch die Akquisition von Rebound™, einem vollständig abgestuften plazentären Allograft-Matrixprodukt von Sequence LifeScience, Inc., erweitert. Es wird erwartet, dass diese Akquisition erheblich zu Celularitys Verkaufszahlen im vierten Quartal 2024 beitragen und den geplanten Gesamtumsatz mit Biomaterialien für 2024 erfüllen wird.
Robert J. Hariri, M.D., Ph.D., Vorsitzender und CEO von Celularity, betonte, dass die Verkaufszahlen von Biomaterialprodukten des Unternehmens in der ersten Hälfte des Jahres 2024 24 Millionen US-Dollar überstiegen und damit die Jahresverkäufe von 2023 übertrafen. Die Hinzufügung von Rebound ergänzt Celularitys bestehendes Portfolio und verbessert die Fähigkeit, eine breitere Patientenpopulation im Wundmanagement und der Weichgewebe-Reparatur anzusprechen.
Diese strategische Akquisition entspricht Celularitys Vision, das Angebot zu erweitern und stärkt die Führungsposition des Unternehmens im Bereich der plazentaren Biomaterialien. Das Unternehmen differenziert sich weiterhin im Regenerationsmedizinmarkt durch die Nutzung der einzigartigen Eigenschaften von Plazentageweben, um fortschrittliche, natürliche Lösungen anzubieten, die darauf ausgelegt sind, die Heilungsergebnisse zu verbessern.
- Acquisition of Rebound™ product expands Celularity's commercial portfolio
- Biomaterial product sales exceeded $24 million in the first half of 2024
- Rebound sales expected to contribute significantly in Q4 2024
- Expansion into broader patient population for wound care and soft tissue repair
- Reinforces leadership in placental-derived biomaterials field
- None.
Insights
The acquisition of Rebound from Sequence LifeScience marks a significant expansion of Celularity's commercial portfolio in the advanced biomaterial products sector. This move is strategically important for several reasons:
- It complements Celularity's existing product line, potentially broadening its market reach in wound care and soft tissue repair.
- The company reported biomaterial product sales exceeding
$24 million in the first half of 2024, already surpassing full-year 2023 sales. - Management expects Rebound to contribute meaningfully to Q4 2024 revenue, supporting the company's full-year 2024 biomaterial sales projections.
With a market cap of about
Celularity's acquisition of Rebound represents a significant advancement in their placental-derived biomaterial portfolio. This move is noteworthy for several reasons:
- Rebound, being a full thickness placental-derived allograft matrix product, likely offers unique regenerative properties that complement Celularity's existing offerings.
- The expansion into wound care and soft tissue repair markets with Rebound could open new avenues for clinical applications and research.
- Celularity's focus on placental-derived products leverages the unique biological properties of these tissues, which have shown promise in regenerative medicine.
From a research perspective, this acquisition could accelerate innovation in placental-derived therapies. It may also provide opportunities for comparative studies between different placental products, potentially leading to optimized treatments for various conditions. The growing commercial success of these products (
FLORHAM PARK, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that it had added to its commercial portfolio of placental-derived advanced biomaterial products with the acquisition of Rebound, a full thickness placental-derived allograft matrix product, from Sequence LifeScience, Inc. (“Sequence”).
“Rebound adds to our portfolio of placental-derived advanced biomaterial products, sales of which through the first half of 2024 were in excess of
Rebound complements Celularity’s existing portfolio of advanced biomaterials, which includes innovative placental-derived products that have shown strong market demand. The addition of Rebound enhances Celularity’s ability to address a broader patient population in wound care and soft tissue repair. By leveraging the unique properties of placental tissues, Celularity continues to differentiate itself in the regenerative medicine market, providing physicians and patients with advanced, natural solutions designed to improve healing outcomes. This acquisition aligns with Celularity’s strategic vision of expanding its offerings and reinforces its leadership in the field of placental-derived biomaterials.
About Celularity
Celularity Inc. (Nasdaq: CELU) is an innovative regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. What sets Celularity apart is its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Celularity’s unique approach, harnessing the placenta’s biology and ready availability, is paving the way for therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as well as within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “might,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. The forward-looking statements in this press release include express or implied statements regarding the impact of the Rebound asset on Celularity’s biomaterial sales for the fourth quarter 2024 and full year 2024, and expectations related to commercial performance. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including but not limited to: Celularity’s liquidity situation; the volatility in Celularity’s stock price; inherent risks in biotechnological development, including with respect to the development of novel advanced biomaterials; and the regulatory approval process; along with those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on July 30, 2024, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor Contact:
Carlos Ramirez
Senior Vice President, Celularity Inc.
Carlos.ramirez@celularity.com
Media Contact:
Raquel Cona / Michaela Fawcett
KCSA Strategic Communications
rcona@kcsa.com / mfawcett@kcsa.com
FAQ
What product did Celularity (CELU) acquire from Sequence LifeScience?
How much were Celularity's (CELU) biomaterial product sales in the first half of 2024?
When is Rebound expected to contribute to Celularity's (CELU) sales?
What areas will the Rebound acquisition help Celularity (CELU) address?
How does the Rebound acquisition align with Celularity's (CELU) strategy?
